Dr. Reddy’s Laboratories (NYSE:RDY) today announced that it has launched the authorized generic version of GlaxoSmithKline’s Imitrex® (sumatriptan succinate) tablets 25mg, 50mg, and 100mg in the United States. Dr. Reddy’s is the first company to launch an authorized generic version of Imitrex® tablets in the US market.
In October 2006, the Company announced that it had settled patent litigation with GlaxoSmithKline relating to sumatriptan succinate tablets, the generic version of GlaxoSmithKline Imitrex® tablets. The specific financial terms and conditions of the settlement have not been disclosed.
GlaxoSmithKline Imitrex® tablets, which are indicated for the acute treatment of migraine attacks in adults, had U.S. sales of $1.29 billion for the 12 month period ending December, 2007 according to IMS.
For further information, please contact:
Genesis Burson- Marsteller
Mansi Chugh
Email : mansi.chugh@bm.com
Tel: + 91 124 4044999-142
Subscribe to our Newsletter!
Be the first to get exclusive offers and the latest news
/afaqs/media/agency_attachments/2024-10-10t065829449z-afaqs_640x480.png)
/afaqs/media/member_avatars/b19bc90752f22463c21493ea40ad04dd26b32ea4045d163717734c0181e00e52.png )
Follow Us/afaqs/media/post_attachments/00d849eba0658c713ef78d58402c3fbda43fbe6734a0ef386268b3db8cfcc0ff.jpg)